Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.

PURPOSE: This phase II trial is studying how well umbilical cord blood works as a source of stem cells in treating patients with types of cancer as well as other diseases.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Milton S. Hershey Medical Center
• Treatments: Antilymphocyte Serum; Busulfan; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Melphalan; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of malignant or non-malignant disease, including but not limited to any of the following:

• Acute myeloid leukemia or acute lymphoblastic leukemia (ALL) with resistant disease beyond first clinical remission (CR)

• ALL in first CR at high-risk because of 1 of the following factors:

• Hypoploidy

• Pseudodiploidy with translocations t(9;22), t(4;11), or t(8;14)

• Elevated WBC at diagnosis as follows:

• > 100,000/mm^3 for patients 6-12 months of age

• > 50,000/mm^3 for patients 10-20 years of age

• > 20,000/mm^3 for patients 21 years of age

• Burkitt's lymphoma/leukemia

• Chronic myelogenous leukemia in first chronic phase or beyond

• Juvenile myelomonocytic leukemia

• Advanced stage or relapsed lymphoma

• Advanced stage or relapsed solid tumors, including any of the following:

• Neuroblastoma

• Ewing's sarcoma

• Rhabdomyosarcoma

• Myelodysplastic syndromes, excluding patients with grade 3 or 4 myelofibrosis

• Familial erythrophagocytic histiocytosis

• Histiocytosis unresponsive to medical management

• Inborn errors of metabolism

• Langerhans cell histiocytosis unresponsive to medical management

• Immune deficiencies, including:

• Severe combined immune deficiency

• Wiskott-Aldrich

• Hemoglobinopathies, including sickle cell disease and thalassemia

• Severe aplastic anemia

• Fanconi's anemia

• Metabolic storage diseases

• Unrelated cord blood donor must be HLA-identical OR may be mismatched for 1, 2, or 3 HLA-loci (A, B, DR)

• No other existing HLA-identical related donor available at the time of transplantation

PATIENT CHARACTERISTICS:

Age

• 21 and under

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• See Disease Characteristics

Hepatic

• Not specified

Renal

• Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified